These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 26275578)

  • 41. Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.
    Des Jarlais D; Duong HT; Pham Minh K; Khuat OH; Nham TT; Arasteh K; Feelemyer J; Heckathorn DD; Peries M; Moles JP; Laureillard D; Nagot N;
    AIDS Care; 2016 Oct; 28(10):1312-5. PubMed ID: 27178119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatitis C Virus Prevalence and Incidence in a Large Nationwide Sample of Patients in Opioid Substitution Treatment in Germany: A Prospective Cohort Study.
    Schulte B; Schmidt CS; Strada L; Rosenkranz M; Schäfer I; Verthein U; Reimer J
    Clin Infect Dis; 2020 May; 70(10):2199-2205. PubMed ID: 31631215
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatitis C virus seroprevalence among patients enrolled at the opioid substitution therapy center in Bihar: A cross-sectional study.
    Kumar A; Mahajan H; Chaturvedi S; Kumar A; Kumar S; Sahoo GC; Das VNR; Pandey K
    PLoS One; 2023; 18(6):e0287333. PubMed ID: 37319276
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Addressing viral hepatitis in the opiate substitution setting: an integrated nursing model of care.
    Fragomeli V; Weltman M
    J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 2():6-11. PubMed ID: 25641224
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effects of needle-sharing and opioid substitution therapy on incidence of hepatitis C virus infection and reinfection in people who inject drugs.
    Aitken CK; Agius PA; Higgs PG; Stoové MA; Bowden DS; Dietze PM
    Epidemiol Infect; 2017 Mar; 145(4):796-801. PubMed ID: 27927256
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.
    Day E; Broder T; Bruneau J; Cruse S; Dickie M; Fish S; Grillon C; Luhmann N; Mason K; McLean E; Trooskin S; Treloar C; Grebely J
    Int J Drug Policy; 2019 Apr; 66():87-93. PubMed ID: 30743093
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study.
    Conway A; Valerio H; Alavi M; Silk D; Treloar C; Hajarizadeh B; Marshall AD; Martinello M; Milat A; Dunlop A; Murray C; Prain B; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Christmass M; Wade A; Montebello M; Dore GJ; Grebely J;
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891535
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
    Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
    Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre.
    Islam MM; Topp L; Conigrave KM; White A; Reid SE; Grummett S; Haber PS; Day CA
    J Subst Abuse Treat; 2012 Dec; 43(4):440-5. PubMed ID: 22938915
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential.
    Perlman DC; Jordan AE; Uuskula A; Huong DT; Masson CL; Schackman BR; Des Jarlais DC
    Int J Drug Policy; 2015 Nov; 26(11):1056-63. PubMed ID: 26050614
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs.
    Midgard H; Finbråten AK; Malme KB; Berg-Pedersen RM; Tanum L; Olsen IC; Bjørnestad R; Dalgard O
    Trials; 2020 Jun; 21(1):524. PubMed ID: 32539853
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: A qualitative study.
    Gunn J; Higgs P
    Res Social Adm Pharm; 2020 Sep; 16(9):1298-1301. PubMed ID: 31003763
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study.
    Marshall AD; Micallef M; Erratt A; Telenta J; Treloar C; Everingham H; Jones SC; Bath N; How-Chow D; Byrne J; Harvey P; Dunlop A; Jauncey M; Read P; Collie T; Dore GJ; Grebely J
    Int J Drug Policy; 2015 Oct; 26(10):984-91. PubMed ID: 26256938
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs.
    Rosenthal ES; Silk R; Mathur P; Gross C; Eyasu R; Nussdorf L; Hill K; Brokus C; D'Amore A; Sidique N; Bijole P; Jones M; Kier R; McCullough D; Sternberg D; Stafford K; Sun J; Masur H; Kottilil S; Kattakuzhy S
    Clin Infect Dis; 2020 Oct; 71(7):1715-1722. PubMed ID: 32009165
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Knowledge and attitudes towards hepatitis C and injecting drug use among mental-health support workers of a community managed organisation.
    Rose G; Cama E; Brener L; Treloar C
    Aust Health Rev; 2013 Nov; 37(5):654-9. PubMed ID: 24160716
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.
    Martin NK; Hickman M; Hutchinson SJ; Goldberg DJ; Vickerman P
    Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S39-45. PubMed ID: 23884064
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C.
    Jack K; Willott S; Manners J; Varnam MA; Thomson BJ
    Aliment Pharmacol Ther; 2009 Jan; 29(1):38-45. PubMed ID: 18945252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?
    Madden A; Hopwood M; Neale J; Treloar C
    PLoS One; 2018; 13(11):e0207226. PubMed ID: 30500863
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection.
    Jafferbhoy H; Miller MH; Dunbar JK; Tait J; McLeod S; Dillon JF
    J Viral Hepat; 2012 Feb; 19(2):112-9. PubMed ID: 22239500
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Dillon JF
    BMJ Open; 2018 Dec; 8(12):e021443. PubMed ID: 30552244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.